REFRACTORY PTLD WITH DLBCL PHENOTYPE TREATED WITH CD19 CAR T-CELL THERAPY

被引：0
|
作者：
Whitman, Abbie [1 ]
Damodharan, Sudarshawn [1 ]
Capitini, Christian [1 ]
机构：
[1] Univ Wisconsin, Madison, WI USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
160
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [1] CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria
    Paillassa, Jerome
    Di Blasi, Roberta
    Chevret, Sylvie
    Bernard, Sophie
    Darmon, Michael
    Meignin, Veronique
    Deau-Fischer, Benedicte
    Camus, Vincent
    Casasnovas, Rene-Olivier
    Cartron, Guillaume
    Chaoui, Driss
    Delwail, Vincent
    Feugier, Pierre
    Fornecker, Luc Mathieu
    Gyan, Emmanuel
    Haioun, Corinne
    Kuhnowski, Frederique
    Malfuson, Jean Valere
    Marolleau, Jean-Pierre
    Morel, Veronique
    Damaj, Gandhi
    Quinquenel, Anne
    Rigaudeau, Sophie
    Salanoubat, Celia
    Salmeron, Geraldine
    Sibon, David
    Azoulay, Elie
    Berquier, Maxime
    Thieblemont, Catherine
    BLOOD, 2019, 134
  • [2] Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL
    Xue, Bin
    Luo, Xiu
    Liu, Yifan
    Zhou, Lili
    Ye, Shiguang
    Li, Shaoguang
    Li, Ping
    Liang, Aibin
    BLOOD, 2023, 142
  • [3] Clinical implications for CAR T cell persistence and functional phenotype in patients treated with CD19 CAR T cell therapy.
    Bochnacka, Oliwia
    Quinn, Suzanne
    Dalheim, Annika
    Scurti, Gina
    Hossain, Nasheed
    Nishimura, Michael
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
  • [4] CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) - the Munich Real Life Experience
    Buecklein, V.
    Schmidt, C.
    Blumenberg, V.
    Reischer, A.
    von, Baumgarten L.
    Voelkl, A.
    Wagner, B.
    Humpe, A.
    Reilich, S.
    Bauer, M.
    Ostermann, H.
    Tischer, J.
    Stemmler, H-J.
    von Bergwelt, M.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 80 - 81
  • [5] Aggressive Lymphoma after CD19 CAR T-Cell Therapy
    Kobbe, Guido
    Bruggemann, Monika
    Baermann, Ben-Niklas
    Wiegand, Laura
    Trautmann, Heiko
    Yousefian, Schayan
    Libertini, Silvana
    Menssen, Hans D.
    Maier, Harald J.
    Ulrich, Peter
    Gao, Jingbo
    Bruch, Peter-Martin
    Liebers, Nora
    Radujkovic, Aleksandar
    Seifert, Marc
    Schniederjohann, Christina
    Paramasivam, Nagarajan
    Fitzgerald, Donnacha
    Seidel, Maximilian
    Esposito, Irene
    Germing, Ulrich
    Cadeddu, Ron-Patrick
    Nachtkamp, Kathrin
    Jaeger, Paul
    Ulrych, Thomas
    Fischer, Johannes C.
    Rox, Jutta M.
    Giesel, Frederik
    Koch, Raphael
    Antoch, Gerald
    Distler, Joerg H. W.
    Meuth, Sven G.
    Jacobsen, Malte
    Hubschmann, Daniel
    Lu, Junyan
    Iaccarino, Ingram
    Haas, Simon
    Damm, Frederik
    Dietrich, Sascha
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (13): : 1217 - 1226
  • [6] Paving the road ahead for CD19 CAR T-cell therapy
    Nellan, Anandani
    Lee, Daniel W.
    CURRENT OPINION IN HEMATOLOGY, 2015, 22 (06) : 516 - 520
  • [7] Secondary malignancy after CD19 CAR T-cell therapy
    Rudek, Loreen Sophie
    Alakus, Hakan
    ONKOLOGIE, 2025,
  • [8] Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma
    Kuipers, Maria T.
    Spanjaart, Anne M.
    Bonifazi, Francesca
    diBlasi, Roberta
    Zinzani, Pier L.
    Thieblemont, Catherine
    Baudet, Mathilde
    Biemond, Bart J.
    Kok, Wouter E. M.
    Kersten, Marie J.
    LEUKEMIA & LYMPHOMA, 2024, 65 (03) : 399 - 402
  • [9] Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
    Wudhikarn, Kitsada
    Tomas, Ana Alarcon
    Flynn, Jessica R.
    Devlin, Sean M.
    Brower, Jamie
    Bachanova, Veronika
    Nastoupil, Loretta J.
    McGuirk, Joseph P.
    Maziarz, Richard T.
    Oluwole, Olalekan O.
    Schuster, Stephen J.
    Porter, David L.
    Bishop, Michael R.
    Riedell, Peter A.
    Perales, Miguel-Angel
    Cell Therapy Consortium
    BLOOD ADVANCES, 2023, 7 (13) : 3192 - 3198
  • [10] A second CD19 CAR T-cell infusion: yes or no?
    Casucci, Monica
    Ciceri, Fabio
    BLOOD, 2021, 137 (03) : 284 - 286
12345